ClinicalTrials.gg
RecruitingNCT07623200EXCALIBUR-ET2Updated Nov 13, 2026

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

A Phase 3 interventional study of INCA033989 and Best Available Treatment in Essential Thrombocythemia, sponsored by Incyte Corporation. Recruiting at 196 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 13, 2026First sites in 4 new countriesSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
426
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 149 studies in Thrombocythemia, Essential with a site in United States — 17 open to participants now, 31 under way, 6 of them phase 3. Thrombocythemia, Essential · United States.

Planned enrollment
2nd of 120
426 · median 45
Started
2026
with 2 others
Phase 3
17 of 149
2 open now
Primary completion
2029-06
later than 22 of 30 live
Registered
148th of 149
by date
Lead sponsor
7 of 149
Incyte Corporation

Among the 149 studies in Thrombocythemia, Essential with a site in United States, this one is the 2nd largest by planned enrollment of the 120 interventional ones that give a count, is one of 3 that started in 2026, is one of 17 in phase 3, reaches primary completion later than 22 of the 30 other live ones, and was the 148th registered.

Thrombocythemia, Essential

229 studies on the registry are indexed under Thrombocythemia, Essential; 37 are open to participants now.

Browse Thrombocythemia, Essential studies →

Open to participants now

17 of the 149 studies in Thrombocythemia, Essential with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Thrombocythemia, Essential studies recruiting now, 29 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Thrombocythemia, Essential with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.

03

Conditions studied

  • Essential Thrombocythemia

Keywords

  • calreticulin (CALR)
  • mutCALR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of high-risk ET.
  • Presence of mutCALR.
  • Prior treatment with at least 1 cytoreductive therapy.

Exclusion criteria

Exclusion Criteria:

  • Presence of any hematologic other than ET.
  • Major bleeding or thrombosis within the last 3 months prior to study enrollment.
  • Any prior allogenic or stem-cell transplantation.
  • Unresolved toxicity ≥ Grade 2 from previous therapy except for stable chronic toxicities (Grade 2) not expected to resolve, such as stable Grade 2 peripheral neuropathy.
  • Prior nonhematologic malignancy except for the following: Malignancy treated with curative intent and with no evidence of active disease for more than 2 years before screening. Adequately treated carcinoma in situ without current evidence of disease.

Other protocol-defined Inclusion/Exclusion Criteria apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
426 participants (estimated)

Study arms

  • Experimental
    INCA033989

    Administered intravenous (IV) in accordance with the protocol-defined requirements.

    Drug: INCA033989

  • Experimental
    Best Available Therapy (BAT)

    Best Available Therapy (BAT) will be selected by the investigator.

    Drug: Best Available Treatment

Interventions

  • Administered intravenous (IV) in accordance with the protocol-defined requirements.

  • DrugBest Available Treatment

    Best Available Therapy (BAT) will be selected by the investigator.

    Also known as: BAT could include:, • HU, • ANA, • PEG interferon alfa-2a, • Ropeginterferon alfa-2b

06

What researchers measure

Primary outcomes

  1. Durable clinicohematologic response (DCR)

    Normalization of platelet and white blood cell (WBC) counts and absence of disease progression as defined in the protocol.

    Time frame: Week 24

Secondary outcomes

  1. Reduction from baseline in calreticulin exon 9 frameshift mutation(s) (mutCLAR) variant allele frequency (VAF)

    Reduction in mutCALR VAF as defined in the protocol.

    Time frame: Week 24

  2. Durable clinicohematologic response (DCR)

    Normalization of platelet and white blood cell (WBC) counts and absence of disease progression as defined in the protocol.

    Time frame: Week 48

  3. Durable partial clinicohematologic response (DPR)

    Improvement of platelet and white blood cell (WBC) counts and absence of disease progression as defined in the protocol.

    Time frame: Week 24

  4. Durable partial clinicohematologic response (DPR)

    Improvement of platelet and white blood cell (WBC) counts and absence of disease progression as defined in the protocol.

    Time frame: Week 48

  5. Longest duration of complete hematologic response (CHR)

    Longest time from documented CHR until the loss of CHR as defined in the protocol.

    Time frame: Up to Week 48

  6. Number of Participants with Treatment Emergent Adverse Events (TEAE)

    Defined as any adverse event occurring after the first dose of study drug until up to 60 days after the last dose of study drug.

    Time frame: Up to Week 48 and 60 days after last dose

  7. TEAEs leading to dose interruptions, dose reductions or discontinuation of study treatment

    TEAEs leading to dose interruptions, dose reductions or discontinuation of study treatment.

    Time frame: Up to Week 48 and 60 days after last dose

  8. Number of participants with a reduction in mutCALR VAF

    Number of participants with a reduction in mutCALR VAF as defined in the protocol.

    Time frame: Week 24 and Week 48

  9. Molecular response

    Overall reduction in mutCALR VAF as defined in the protocol.

    Time frame: Week 24 and Week 48

  10. Change from baseline in Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) total symptom score (TSS)

    Defined as the proportion of participants who achieve a protocol defined reduction in TSS.

    Time frame: Up to Week 48

  11. Change from baseline in Brief Fatigue Inventory (BFI) fatigue score

    The BFI is a 9 item scored from 0 (no fatigue) -10 (as bad as you can imagine), items are averaged with total score from 0-10, with higher score indicating more fatigue.

    Time frame: Up to Week 48

  12. Patient Global Impression of Change (PGIC) score

    The PGIC is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.

    Time frame: Up to Week 48

07

Study locations

9 of 196 sites recruiting
  • University of Alabama At Birmingham Comprehensive Cancer Center
    Birmingham, Alabama 35205, United States
    Not yet recruiting
  • Banner Md Anderson Cancer Center
    Gilbert, Arizona 85234, United States
    Not yet recruiting
  • City of Hope Medical Center
    Duarte, California 91010, United States
    Recruiting
  • Marin Cancer Care
    Greenbrae, California 94904, United States
    Recruiting
  • University of California, San Diego-Moores Cancer Center
    La Jolla, California 92037, United States
    Not yet recruiting
  • University of California, Los Angeles Medical Center
    Los Angeles, California 90095, United States
    Not yet recruiting
  • Stanford Cancer Center
    Palo Alto, California 94304, United States
    Not yet recruiting
  • Rocky Mountain Cancer Centers-Lone Tree
    Lone Tree, Colorado 80124, United States
    Not yet recruiting
  • Medstar Georgetown Medical Center, Inc
    Washington D.C., District of Columbia 20007, United States
    Not yet recruiting
  • Florida Cancer Specialists & Research Institute
    Fort Myers, Florida 33901, United States
    Not yet recruiting
  • University of Miami Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
    Not yet recruiting
  • Cleveland Clinic
    Weston, Florida 33331, United States
    Not yet recruiting
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
    Not yet recruiting
  • University of Chicago
    Chicago, Illinois 60637, United States
    Not yet recruiting
  • The University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
    Not yet recruiting
  • Our Lady of the Lake Medical Center
    Baton Rouge, Louisiana 70808, United States
    Not yet recruiting
  • Johns Hopkins Medicine-the Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21231, United States
    Not yet recruiting
  • Maryland Oncology Hematology, P.A.
    Columbia, Maryland 21044, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • Beth Israel Deaconess Medical Center (Bidmc)
    Boston, Massachusetts 02215, United States
    Not yet recruiting
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
    Not yet recruiting
  • University of Michigan Rogel Cancer Center Adult Bone Marrow Transplant Clinic
    Ann Arbor, Michigan 48109-4000, United States
    Not yet recruiting
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
    Not yet recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Not yet recruiting
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-7680, United States
    Not yet recruiting
  • John Theurer Cancer Center, Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
    Not yet recruiting
  • Icahn School of Medicine At Mount Sinai
    New York, New York 10029, United States
    Not yet recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Not yet recruiting
  • Weill Cornell Medical College - Newyork-Presbyterian Hospita
    New York, New York 10065, United States
    Not yet recruiting
  • Strong Memorial Hospital University of Rochester Medical Center
    Rochester, New York 14642, United States
    Not yet recruiting
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
    Not yet recruiting
  • Cleveland Clinic Taussig Cancer Ctr
    Cleveland, Ohio 44195, United States
    Not yet recruiting
  • Willamette Valley Cancer Institute and Research Center
    Eugene, Oregon 97401, United States
    Recruiting
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
    Not yet recruiting
  • Thomas Jefferson University Sidney Kimmel Medical College
    Philadelphia, Pennsylvania 19107, United States
    Not yet recruiting
  • Medical University of South Carolina, Hollings Cancer Center
    Charleston, South Carolina 29425, United States
    Not yet recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Not yet recruiting
  • Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
    Not yet recruiting
  • Baylor St Luke'S Medical Center
    Houston, Texas 77030, United States
    Not yet recruiting
  • The University of Texas-Md Anderson Cancer Center
    Houston, Texas 77030, United States
    Not yet recruiting
  • Ut Health Science Center At San Antonio
    San Antonio, Texas 78229, United States
    Not yet recruiting
  • Texas Oncology-Tyler
    Tyler, Texas 75702, United States
    Recruiting
  • Huntsman Cancer Institute At University of Utah
    Salt Lake City, Utah 84112, United States
    Not yet recruiting
  • Virginia Oncology Associates (Brock Cancer Center)
    Norfolk, Virginia 23502, United States
    Not yet recruiting
  • University of Washington - Fred Hutch Cancer Center
    Seattle, Washington 98109, United States
    Not yet recruiting
  • Blacktown Cancer & Haematology Centre-Blacktown Hospital
    Blacktown, New South Wales 02148, Australia
    Recruiting
  • Gosford Hospital (Gh) - Central Coast Cancer Centre
    Gosford, New South Wales 02250, Australia
    Not yet recruiting
  • Liverpool Hospital - South Western Sydney Local Health District
    Liverpool, New South Wales 02170, Australia
    Not yet recruiting
  • Sunshine Coast University Hospital
    Birtinya, Queensland 04575, Australia
    Not yet recruiting
  • Royal Brisbane and Women'S Hospital
    Brisbane, Queensland 04029, Australia
    Not yet recruiting
  • Icon Cancer Centre Adelaide
    Kurralta Park, South Australia 05037, Australia
    Not yet recruiting
  • Peter Maccallum Cancer Centre
    Melbourne, Victoria 03000, Australia
    Not yet recruiting
  • Box Hill Hospital
    Melbourne, Victoria 03128, Australia
    Recruiting
  • Rockingham General Hospital
    Cooloongup, 06168, Australia
    Not yet recruiting
  • The Canberra Hospital
    Garran, 02605, Australia
    Not yet recruiting
  • Royal Perth Hospital
    Perth, 06000, Australia
    Not yet recruiting
  • Lkh - Medizinische Universitaet Graz
    Graz, 08036, Austria
    Not yet recruiting
  • Landeskrankenhaus (Lkh) Leoben - Standort Leoben
    Leoben, 08700, Austria
    Not yet recruiting
  • Ordensklinikum Linz Gmbh Elisabethinen
    Linz, 04020, Austria
    Not yet recruiting
  • Medizinische Universitaet Wien, Akh Wien
    Vienna, 01090, Austria
    Not yet recruiting
  • Klinikum Wels-Grieskirchen Gmbh
    Wels, 04600, Austria
    Not yet recruiting
  • Jules Bordet Lnstitute
    Anderlecht, 01070, Belgium
    Not yet recruiting
  • Centre Hospitalier Universitaire (Chu) Brugmann (Brugmann University Hospital (Uh)) - Victor Horta
    Brussels, 1020, Belgium
    Not yet recruiting
  • Universitair Ziekenhuis Leuven
    Leuven, 03000, Belgium
    Not yet recruiting
  • Centre Hospitalier Universitaire de Liege - Sart Tilman
    Liège, 04000, Belgium
    Not yet recruiting
  • Algemeen Ziekenhuis Deltaaretaie
    Roeselare, 08800, Belgium
    Not yet recruiting
  • Universite Catholique de Louvain (Ucl) - Cliniques Universitaires Saint-Luc
    Woluwe-Saint-Lambert, 01200, Belgium
    Not yet recruiting
  • St. Paul'S Hospital (Sph), Providence Health Care, University of British Columbia
    Vancouver, British Columbia V6Z 1Y6, Canada
    Not yet recruiting
  • Juravinski Cancer Centre-Hamilton Health Sciences (Hhs)
    Hamilton, Ontario L8V 5C2, Canada
    Not yet recruiting
  • Queens University, Kingston General Hospital (Kgh), Kingston Health Sciences Centre (Khsc)
    Kingston, Ontario K7L 2V7, Canada
    Not yet recruiting
  • University Health Network (Uhn) - Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • Sir Mortimer B. Davis - Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
    Not yet recruiting
  • McGill University Health Centre - Glen Site, Centre For Innovative Medicine
    Montreal, Quebec H4A 3J1, Canada
    Not yet recruiting
  • Hotel-Dieu de Levis
    Québec, Quebec G6V 3Z1, Canada
    Not yet recruiting
  • Fakultni Nemocnice Brno
    Brno, 625 00, Czechia
    Not yet recruiting
  • Fakultni Nemocnice Ostrava
    Ostrava-poruba, 708 52, Czechia
    Not yet recruiting
  • Faculty Hospital Kralovske Vinohrady
    Prague, 100 34, Czechia
    Not yet recruiting
  • Vseobecna Fakultni Nemocnice V Praze
    Prague, 12808, Czechia
    Not yet recruiting
  • Ustav Hematologie A Krevni Transfuze (Uhkt)
    Prague, 12820, Czechia
    Not yet recruiting
  • Chu D'Amiens-Picardie - Hopital Sud
    Amiens, 80054, France
    Not yet recruiting
  • Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest
    Bordeaux, 33076, France
    Not yet recruiting
  • Chu de Brest Hopital de La Cavale Blanche Cic Hematologie
    Brest, 29200, France
    Not yet recruiting
  • Hospital Henri Mondor
    Créteil, 94000, France
    Not yet recruiting
  • Hopital Bicetre - Paris Sud (Ap-Hp)
    Le Kremlin-Bicêtre, 94275, France
    Not yet recruiting
  • Centre Hospitalier Universitaire de Nice,Hopital L Archet
    Nice, 06200, France
    Not yet recruiting
  • Hospital Saint-Louis - Aphp
    Paris, 75010, France
    Not yet recruiting
  • Centre Hospitalier Universitaire de Poitiers La Miletrie
    Poitiers, 86021, France
    Not yet recruiting
  • Institut Claudius Regaud Cancer Comprehensive Center - Iuct Oncopole
    Toulouse, 31059, France
    Not yet recruiting
  • Israel-Georgian Medical Research Clinic Healthycore
    Tbilisi, 00112, Georgia
    Not yet recruiting
  • K. Eristavi National Center of Experimental and Clinical Surgery
    Tbilisi, 00159, Georgia
    Not yet recruiting
  • Institute of Hematology and Transfusiology
    Tbilisi, 00160, Georgia
    Not yet recruiting
  • Medulla - Clinics and Medical Centers
    Tbilisi, 00168, Georgia
    Not yet recruiting
  • Uniklinik Rwth Aachen Medizinische Klinik Iv
    Aachen, 52074, Germany
    Not yet recruiting
  • Charite - Universitaetsmedizin Berlin
    Berlin, 10117, Germany
    Not yet recruiting
  • Bag Onkologische Gemeinschaftspraxis Illmer Jacobasch Wolf Freiberg-Richter Fae Fur Innere Medizi
    Dresden, 01307, Germany
    Not yet recruiting
  • Universitaetsklinikum Freiburg
    Freiburg im Breisgau, 79106, Germany
    Not yet recruiting
  • Universitaetsklinikum Halle
    Halle, 06120, Germany
    Not yet recruiting
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
    Not yet recruiting
  • Medizinische Hochschule Hannover, Hannover Medical School
    Hanover, 30625, Germany
    Not yet recruiting
  • Universitaetsklinikum Des Saarlandes Und Medizinische Fakultaet Der Universitaet Des Saarlandes
    Homburg, 66421, Germany
    Not yet recruiting

Showing the first 100 of 196 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Jun 2029, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 3, 2026
StartActual
Sep 8, 2026
Primary completionEst.
Jun 15, 2029
CompletionEst.
Nov 1, 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
30 sites added, 9 sites removed — first sites in Singapore, Georgia, New Zealand and Turkey (Türkiye). 8 sites changed recruiting status (8 now recruiting)
Show 8 sites
  • City of Hope Medical Center · Duarte, United StatesNot yet recruiting→Recruiting
  • Texas Oncology-Tyler · Tyler, United StatesNot yet recruiting→Recruiting
  • Blacktown Cancer & Haematology Centre-Blacktown Hospital · Blacktown, AustraliaNot yet recruiting→Recruiting
  • Box Hill Hospital · Melbourne, AustraliaNot yet recruiting→Recruiting
  • Maryland Oncology Hematology, P.A. · Columbia, United StatesNot yet recruiting→Recruiting
  • Willamette Valley Cancer Institute and Research Center · Eugene, United StatesNot yet recruiting→Recruiting
  • University Health Network (Uhn) - Princess Margaret Cancer Centre · Toronto, CanadaNot yet recruiting→Recruiting
  • Osaka Metropolitan University Hospital · Osaka, JapanNot yet recruiting→Recruiting
Show 30 added (9 United States, 9 Turkey (Türkiye), 4 Georgia, 2 Australia, 2 Singapore, 1 Canada, 1 Germany, 1 New Zealand, 1 Spain)
  • University of Alabama At Birmingham Comprehensive Cancer Center · Birmingham, United States
  • Our Lady of the Lake Medical Center · Baton Rouge, United States
  • Baylor Charles A. Sammons Cancer Center · Dallas, United States
  • Virginia Oncology Associates (Brock Cancer Center) · Norfolk, United States
  • Rockingham General Hospital · Cooloongup, Australia
  • Singapore General Hospital · Singapore, Singapore
  • University of California, San Diego-Moores Cancer Center · La Jolla, United States
  • Winship Cancer Institute of Emory University · Atlanta, United States
  • Icon Cancer Centre Adelaide · Kurralta Park, Australia
  • Juravinski Cancer Centre-Hamilton Health Sciences (Hhs) · Hamilton, Canada
  • Israel-Georgian Medical Research Clinic Healthycore · Tbilisi, Georgia
  • K. Eristavi National Center of Experimental and Clinical Surgery · Tbilisi, Georgia
  • Medulla - Clinics and Medical Centers · Tbilisi, Georgia
  • Bag Onkologische Gemeinschaftspraxis Illmer Jacobasch Wolf Freiberg-Richter Fae Fur Innere Medizi · Dresden, Germany
  • Aotearoa Clinical Trials Trust (Actt) -Middlemore Hospital · Auckland, New Zealand
  • National University Hospital, National University Cancer Institute Singapore · Singapore, Singapore
  • Puerta de Hierro Majadahonda University Hospital · Majadahonda, Spain
  • Ankara Bilkent City Hospital · Ankara, Turkey (Türkiye)
  • Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · Ankara, Turkey (Türkiye)
  • Gazi University Faculty of Medicine · Ankara, Turkey (Türkiye)
  • Trakya University Faculty of Medicine · Edirne, Turkey (Türkiye)
  • Ege Universitesi (Ege University) · Izmir, Turkey (Türkiye)
  • Kocaeli Universitesi Tip Fakultesi · Kocaeli, Turkey (Türkiye)
  • Vm Medical Park Mersin Hastanesi · Mezitli, Turkey (Türkiye)
  • Sakarya University Training and Research Hospital · Sakarya, Turkey (Türkiye)
  • Istanbul Florence Nightingale Hospital · Şişli, Turkey (Türkiye)
  • University of Nebraska Medical Center · Omaha, United States
  • Medical University of South Carolina, Hollings Cancer Center · Charleston, United States
  • Baylor St Luke'S Medical Center · Houston, United States
  • Institute of Hematology and Transfusiology · Tbilisi, Georgia
Show 9 removed
  • Winship Cancer Institute of Emory University · Atlanta, United States
  • Ostfold Hospital · Grålum, Norway
  • Vanderbilt University Medical Center · Nashville, United States
  • Rutgers Cancer Institute of New Jersey · New Brunswick, United States
  • Margaret and Charles Juravinski Cancer Center · Hamilton, Canada
  • Bag Onkologische Gemeinschaftspraxis Illmer, Jacobasch, Wolf, Freiberg-Richter Fae Fur Innere Medizi · Dresden, Germany
  • Uniwersytecki Szpital Kliniczny Nr 1 W Lublinie · Lublin, Poland
  • Hospital Universitario Puerta de Hierro de Majadahonda · Majadahonda, Spain
  • Winship Cancer Institute of Emory University · Atlanta, United States
across 5 updates, Oct 8, 2026 – Nov 13, 2026
Show all 5 updates
  1. Nov 13, 2026
    4 sites added. 4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Maryland Oncology Hematology, P.A. · Columbia, United StatesNot yet recruiting→Recruiting
    • Willamette Valley Cancer Institute and Research Center · Eugene, United StatesNot yet recruiting→Recruiting
    • University Health Network (Uhn) - Princess Margaret Cancer Centre · Toronto, CanadaNot yet recruiting→Recruiting
    • Osaka Metropolitan University Hospital · Osaka, JapanNot yet recruiting→Recruiting
    Show 4 added (3 United States, 1 Georgia)
    • University of Nebraska Medical Center · Omaha, United States
    • Medical University of South Carolina, Hollings Cancer Center · Charleston, United States
    • Baylor St Luke'S Medical Center · Houston, United States
    • Institute of Hematology and Transfusiology · Tbilisi, Georgia
  2. Nov 5, 2026
    1 site removed
    Show 1 removed
    • Winship Cancer Institute of Emory University · Atlanta, United States
    + 1 other change: verification date
  3. Oct 30, 2026
    20 sites added, 5 sites removed — first sites in Georgia, New Zealand and Turkey (Türkiye). 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Texas Oncology-Tyler · Tyler, United StatesNot yet recruiting→Recruiting
    • Blacktown Cancer & Haematology Centre-Blacktown Hospital · Blacktown, AustraliaNot yet recruiting→Recruiting
    • Box Hill Hospital · Melbourne, AustraliaNot yet recruiting→Recruiting
    Show 20 added (9 Turkey (Türkiye), 3 Georgia, 2 United States, 1 Australia, 1 Canada, 1 Germany, 1 New Zealand, 1 Singapore, 1 Spain)
    • University of California, San Diego-Moores Cancer Center · La Jolla, United States
    • Winship Cancer Institute of Emory University · Atlanta, United States
    • Icon Cancer Centre Adelaide · Kurralta Park, Australia
    • Juravinski Cancer Centre-Hamilton Health Sciences (Hhs) · Hamilton, Canada
    • Israel-Georgian Medical Research Clinic Healthycore · Tbilisi, Georgia
    • K. Eristavi National Center of Experimental and Clinical Surgery · Tbilisi, Georgia
    • Medulla - Clinics and Medical Centers · Tbilisi, Georgia
    • Bag Onkologische Gemeinschaftspraxis Illmer Jacobasch Wolf Freiberg-Richter Fae Fur Innere Medizi · Dresden, Germany
    • Aotearoa Clinical Trials Trust (Actt) -Middlemore Hospital · Auckland, New Zealand
    • National University Hospital, National University Cancer Institute Singapore · Singapore, Singapore
    • Puerta de Hierro Majadahonda University Hospital · Majadahonda, Spain
    • Ankara Bilkent City Hospital · Ankara, Turkey (Türkiye)
    • Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · Ankara, Turkey (Türkiye)
    • Gazi University Faculty of Medicine · Ankara, Turkey (Türkiye)
    • Trakya University Faculty of Medicine · Edirne, Turkey (Türkiye)
    • Ege Universitesi (Ege University) · Izmir, Turkey (Türkiye)
    • Kocaeli Universitesi Tip Fakultesi · Kocaeli, Turkey (Türkiye)
    • Vm Medical Park Mersin Hastanesi · Mezitli, Turkey (Türkiye)
    • Sakarya University Training and Research Hospital · Sakarya, Turkey (Türkiye)
    • Istanbul Florence Nightingale Hospital · Şişli, Turkey (Türkiye)
    Show 5 removed
    • Rutgers Cancer Institute of New Jersey · New Brunswick, United States
    • Margaret and Charles Juravinski Cancer Center · Hamilton, Canada
    • Bag Onkologische Gemeinschaftspraxis Illmer, Jacobasch, Wolf, Freiberg-Richter Fae Fur Innere Medizi · Dresden, Germany
    • Uniwersytecki Szpital Kliniczny Nr 1 W Lublinie · Lublin, Poland
    • Hospital Universitario Puerta de Hierro de Majadahonda · Majadahonda, Spain
  4. Oct 15, 2026
    1 site added, 1 site removed — first site in Singapore
    Show site
    • Singapore General Hospital · Singapore, Singapore
    Show 1 removed
    • Vanderbilt University Medical Center · Nashville, United States
  5. Oct 8, 2026
    5 sites added, 2 sites removed. City of Hope Medical Center is now Recruiting
    Show 5 added (4 United States, 1 Australia)
    • University of Alabama At Birmingham Comprehensive Cancer Center · Birmingham, United States
    • Our Lady of the Lake Medical Center · Baton Rouge, United States
    • Baylor Charles A. Sammons Cancer Center · Dallas, United States
    • Virginia Oncology Associates (Brock Cancer Center) · Norfolk, United States
    • Rockingham General Hospital · Cooloongup, Australia
    Show 2 removed
    • Winship Cancer Institute of Emory University · Atlanta, United States
    • Ostfold Hospital · Grålum, Norway
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07623200
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Sep 8, 2026
Primary completion
Jun 15, 2029 (estimated)
Completion
Nov 1, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-mutant Calreticulin Monoclonal Antibody INCA033989

Start the discussion